Last updated: February 24, 2026
What Is NDC 50742-0284?
NDC 50742-0284 is Umedica's BTXA (Botulinum Toxin Type A) product. It is used in therapeutic and aesthetic treatments, primarily for muscle spasticity, dystonia, and wrinkle reduction.
Market Overview
Therapeutic and Aesthetic Segments
The global botulinum toxin market exceeded $6 billion in 2022 and is projected to reach $10 billion by 2027, with a compound annual growth rate (CAGR) of approximately 10%. This expansion is driven by consistent demand in aesthetic applications and increasing approvals for therapeutic uses.
Key Market Drivers
- Rising prevalence of neurological disorders (e.g., cervical dystonia, spasticity)
- Growing demand for minimally invasive cosmetic procedures
- Broadening regulatory approval landscape
- Innovations in toxin formulations and delivery systems
Competitive Landscape
Major players include:
| Company |
Market Share |
Notable Products |
Estimated Market Position (2022) |
| AbbVie (Botox) |
50% |
Botox, Botox Cosmetic |
Dominant |
| Medytox |
15% |
Nabota, Neuronox |
Second tier |
| Evolus |
10% |
Jeuveau |
Emerging |
| Umedica |
5-8% |
BTXA (NDC 50742-0284) |
Niche competitor |
Distribution Channels
- Hospitals and specialty clinics account for roughly 60% of sales.
- Medical spas and aesthetic clinics constitute approximately 25%.
- Direct sales and distribution partnerships handle the remainder.
Pricing and Cost Structure
Penetration and Pricing Strategy
Umedica’s BTXA has entered primarily through negotiated pricing with healthcare providers, with per-unit costs approximately 10-15% lower than market leaders, leveraging manufacturing efficiencies.
Price Benchmarks
| Product |
Average Price per 100 Units |
Approximate Cost (2022) |
| Botox (AbbVie) |
$1,200 - $1,500 |
$800 - $1,000 |
| Jeuveau |
$1,000 - $1,250 |
$700 - $900 |
| Nabota |
$1,100 - $1,400 |
$750 - $950 |
| Umedica (BTXA) |
Estimated $950 - $1,200 |
Estimated $600 - $800 |
Umedica’s product is positioned at a 15-20% discount compared to top-tier competitors. If Umedica maintains quality, its price point offers a competitive edge without significant margin loss.
Market Entry and Growth Potential
Regulatory Pathways
Umedica’s BTXA holds approval in select markets, including India, Taiwan, and parts of Latin America. Further approvals (e.g., US FDA) could expand access by 2024-2025.
Strategic Opportunities
- Partner with distributors in emerging markets
- Expand indications to include hyperhidrosis and overactive bladder
- Invest in clinical data to gain FDA and EMA approval
Risks and Challenges
- Market share resistance from entrenched competitors
- Regulatory delays or denials
- Price pressure from hospital procurement negotiations
Price Projection Scenarios (2023-2027)
| Year |
Conservative |
Moderate |
Aggressive |
| 2023 |
$950 - $1,100 |
$1,000 - $1,150 |
$1,050 - $1,200 |
| 2024 |
$900 - $1,050 |
$950 - $1,150 |
$1,000 - $1,250 |
| 2025 |
$850 - $1,000 |
$900 - $1,100 |
$950 - $1,200 |
| 2026 |
$800 - $950 |
$850 - $1,050 |
$900 - $1,150 |
| 2027 |
$750 - $900 |
$800 - $1,000 |
$850 - $1,100 |
In a moderate scenario, per-unit prices decline gradually as production scales up, economies of scale improve, and competitive pricing intensifies.
Financial Implications
- Margins could range from 15-25% depending on volume and negotiations.
- Larger market access expansion could drive volume-driven margin improvements.
- Premium pricing is sustainable with proven efficacy and safety data.
Key Takeaways
- Umedica’s BTXA is priced roughly 15-20% below top competitors, providing a competitive differential.
- Growth hinges on regulatory approvals and market expansion, particularly in North America and Europe.
- Price decline over the next five years is expected, aligned with increased competition and manufacturing efficiencies.
- Strategic partnerships and indications expansion could mitigate pricing pressures.
FAQs
Q1: When might Umedica’s BTXA gain FDA approval?
Potentially between 2024 and 2025 if clinical trial data supports safety and efficacy for US submission.
Q2: How does Umedica’s pricing compare to major competitors?
It is approximately 15-20% lower on a per-unit basis, making it more accessible for price-sensitive markets.
Q3: What are the key barriers to market penetration?
Brand loyalty among providers, regulatory hurdles, and price pressures from established players.
Q4: Which markets offer the most growth potential?
Emerging markets in Asia, Latin America, and regulatory expansion in North America and Europe.
Q5: How will competitive dynamics influence Umedica’s pricing?
Market entry by new entrants and price-based competition will likely cause gradual price reductions over time.
References
- MarketsandMarkets. (2022). Botulinum Toxin Market by Application, End-User, and Region – Global Forecast to 2027.
- U.S. Food and Drug Administration. (2022). Botox (onabotulinumtoxinA) approval details.
- Umedica. (2022). Corporate website and product information.
- Allied Market Research. (2022). Aesthetic Botulinum Toxin Market Trends and Forecasts.
